HIV / AIDS in the News

Gilead Topples On A Surprise Setback For Its 99.9% Effective HIV Drug - Investor's Business Daily

 

Bolstering HIV Cure Research in the Current Political Context: A Statement from The Well Project and the Women's Research Initiative on HIV/AIDS - POZ - Health, Life and HIV

 

Recon: CVS won’t add Gilead’s HIV PREP jab to coverage lists; J&J to make $2B in US drug manufacturing - Regulatory Affairs Professionals Society | RAPS

 

Federal and State Funding Cuts Increase HIV Risk in Dallas County - POZ - Health, Life and HIV

 

For now, CVS declines to cover Gilead's long-acting HIV PrEP treatment Yeztugo - Fierce Pharma

 

Uncovering Molecular Connections in HIV Comorbidities: Insights from a Big Data Study - BIOENGINEER.ORG

 

Akron organization loses federal housing funding for people living with HIV, at-risk LGBTQ+ adults - Cleveland.com

 

Gilead Sciences Stock (GILD) Turns Negative As CVS Says No To HIV Prevention Drug - TipRanks

 

Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying. - Barron's

 

Gilead Sciences’ New HIV Treatment Study: A Potential Game-Changer? - TipRanks

 

What Happens in Vegas Shouldn’t Stay in Vegas: Lessons from the HIV Frontlines - POZ - Health, Life and HIV

 

Lambda Legal announces settlement in solitary confinement, HIV discrimination case against MDOC - Dallas Voice

 

How to prevent and fight HIV in Black women - EBONY Magazine

 

Gilead shares drop after CVS delays coverage for HIV prevention shot - MSN

 

CVS Health Excludes Gilead Sciences’ New HIV Prevention Drug from Commercial Insurance Plans - geneonline.com

 

Comorbidities in HIV: Big data study reveals molecular links - Medical Xpress

 

The lab coat just got queer - Out Magazine

 

Single-Dose AAV-bNAb Gene Therapy at Birth Holds Potential for Prolonged HIV-1 Immunity - Docwire News

 

Gilead Falls as CVS Hasn’t Yet Added PrEP HIV Shot to Drug Plans - Bloomberg.com

 

HIV Unwrapped - Out Magazine

 

Pharmalittle: We're reading about Gilead's HIV drug, FDA speeding review of a rare disease drug, and more - statnews.com

 

Gilead Sciences Plunges 3.5% as CVS Drops HIV Shot Coverage - AInvest

 

Envelope immunogen carrying multiple epitopes for HIV - BioWorld MedTech

 

Why Is Gilead Sciences Stock Falling Thursday? - CVS Health (NYSE:CVS), Gilead Sciences (NASDAQ:GILD) - Benzinga

 

At First Baptist Church, HIV/AIDS quilts become a sanctuary of memory and love - Austin American-Statesman

 

Hope rises as HIV vaccine research shows major progress - ioplus.nl

 

'It just doesn’t look the same': Southern HIV prevention leaders confront new political landscape - Rough Draft Atlanta

 

CVS Health reportedly excludes coverage for Gilead’s new HIV drug for now - Seeking Alpha

 

Preserved corpses at ‘HIV temple’ to be cremated - bangkokpost.com

 

The Impact of Payer Resistance on Biotech Innovation: Gilead's Yeztugo and the Future of HIV Prevention - AInvest